Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 429

Results For "CRE"

4406 News Found

PI Industries acquires API business of Ind Swift Laboratories
News | August 02, 2021

PI Industries acquires API business of Ind Swift Laboratories

Turnover of API division of ISLL stood at Rs 856.58 crore


Windlas Biotech opens for subscription this week
Biotech | August 02, 2021

Windlas Biotech opens for subscription this week

Proceeds from the IPO will be used for the expansion of the Dehradun facility.


Zydus Wellness Q1FY22 consolidated net profit at Rs. 130.80 Cr
News | July 31, 2021

Zydus Wellness Q1FY22 consolidated net profit at Rs. 130.80 Cr

The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.


RPG Life Sciences Q1FY22 PAT surges to Rs. 13.58 Cr
News | July 29, 2021

RPG Life Sciences Q1FY22 PAT surges to Rs. 13.58 Cr

The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.


Alembic Pharmaceuticals Q1FY22 net slides to Rs. 164.52 Cr
News | July 27, 2021

Alembic Pharmaceuticals Q1FY22 net slides to Rs. 164.52 Cr

The US business faced price erosion due to increased competition.


Sun Pharma signs Cassiopea for license and supply agreements
News | July 27, 2021

Sun Pharma signs Cassiopea for license and supply agreements

Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older


GlaxoSmithKline delivers 19% revenue growth for Q1 FY22
News | July 27, 2021

GlaxoSmithKline delivers 19% revenue growth for Q1 FY22

The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited


Lonza reports strong momentum in H1 2021
News | July 24, 2021

Lonza reports strong momentum in H1 2021

The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth


Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr
News | July 23, 2021

Biocon Q1FY22 revenue up 6% at Rs 1,808 Cr

Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).


Syngene Q1 FY22 revenue grows 41%
News | July 21, 2021

Syngene Q1 FY22 revenue grows 41%

The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels